"FDA Panel Turns Down Glaxo Drug" and related posts

Thursday, December 2, 2010

DailyMarkets.com

GlaxoSmithKline's (NYSE:GSK) efforts to get its prostate cancer drug, Avodart, approved for an additional indication faced a stumbling block recently with an advisory panel of the US Food and Drug Administration (FDA) voting against the label expansion.
See all 11 blogs.



0 comments:

Post a Comment

 
 
 

Popular Posts